Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

Phase 2

Active, not recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Radiation: Radiotherapy
Drug: Atezolizumab
Drug: Cisplatin

First Posted Date: 2018-08-02

Last Posted Date: 2024-12-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 189

Registration Number: NCT03612791

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase 2

Recruiting

Conditions: Stage III Bladder Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma
Infiltrating Bladder Urothelial Carcinoma

Interventions: Drug: Gemcitabine Hydrochloride
Drug: Cisplatin
Biological: Pegfilgrastim
Procedure: Conventional Surgery
Procedure: Radical Cystectomy
Other: Chemoradiotherapy

First Posted Date: 2018-08-01

Last Posted Date: 2024-12-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 271

Registration Number: NCT03609216

Locations: 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Henry Ford River District Hospital, East China Township, Michigan, United States
🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States

and more 409 locations

Herzuma-capecitabine/Cisplatin for Gastric Cancer

Phase 2

Conditions: Metastatic Cancer
HER-2 Positive Gastric Cancer

Interventions: Drug: Trastuzumab
Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2018-07-17

Last Posted Date: 2018-07-17

Lead Sponsor: Sung Yong Oh

Target Recruit Count: 50

Registration Number: NCT03588533

Locations: 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Phase 3

Recruiting

Conditions: ENSAT Stage I Adrenal Cortex Carcinoma
ENSAT Stage II Adrenal Cortex Carcinoma
ENSAT Stage III Adrenal Cortex Carcinoma

Interventions: Drug: Mitotane
Drug: Cisplatin
Other: Quality-of-Life Assessment
Drug: Etoposide

First Posted Date: 2018-07-11

Last Posted Date: 2024-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 240

Registration Number: NCT03583710

Locations: 🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden
🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪
Akademiska Sjukhuset, Uppsala, Sweden

and more 5 locations

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1

Completed

Conditions: Bladder Small Cell Neuroendocrine Carcinoma
Castration-Resistant Prostate Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Prostate Carcinoma Metastatic in the Bone
Prostate Neuroendocrine Neoplasm
Prostate Small Cell Carcinoma
Stage III Bladder Cancer AJCC V8
Stage III Prostate Cancer AJCC V8
Stage III Urethral Cancer AJCC V8

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Drug: Etoposide
Biological: Pembrolizumab

First Posted Date: 2018-07-11

Last Posted Date: 2023-04-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT03582475

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Apatinib
Drug: paclitaxel
Drug: cisplatin

First Posted Date: 2018-07-09

Last Posted Date: 2021-07-09

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 200

Registration Number: NCT03580395

Locations: 🇨🇳
Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei, China

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Phase 2

Active, not recruiting

Conditions: Stage IB Intrahepatic Cholangiocarcinoma AJCC v8
Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
Resectable Cholangiocarcinoma
Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Stage II Intrahepatic Cholangiocarcinoma AJCC v8
Stage III Intrahepatic Cholangiocarcinoma AJCC v8

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2018-07-09

Last Posted Date: 2023-05-06

Lead Sponsor: Emory University

Target Recruit Count: 31

Registration Number: NCT03579771

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 4 locations

Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer

Phase 3

Withdrawn

Conditions: Stage IIB Gallbladder Cancer AJCC v8
Stage I Gallbladder Cancer AJCC v8
Stage II Gallbladder Cancer AJCC v8
Stage IIA Gallbladder Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
Stage IIIB Gallbladder Cancer AJCC v8

Interventions: Drug: Capecitabine
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2018-07-09

Last Posted Date: 2020-06-05

Lead Sponsor: Emory University

Registration Number: NCT03579758

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Stanford, California, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 2 locations

Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer

Phase 2

Conditions: Esophageal Neoplasms
Concurrent Chemoradiotherapy
Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel
Drug: Cisplatin
Drug: Fluorouracil
Radiation: chemoradiotherapy
Procedure: Ivor Lewis esophagogastrectomy

First Posted Date: 2018-07-06

Last Posted Date: 2018-07-06

Lead Sponsor: Mona Frolova

Target Recruit Count: 48

Registration Number: NCT03579004

Locations: 🇷🇺
Russian Cancer Research Center named after N.N.Blokhin RAMS, Moscow, Russian Federation
🇷🇺
Alexey Tryakin, Moscow, Russian Federation

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

Phase 3

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Cisplatin
Radiation: RT
Drug: Nivolumab

First Posted Date: 2018-07-03

Last Posted Date: 2024-07-05

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 680

Registration Number: NCT03576417

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy